Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Voom has developed a multi-platform wellness program to address both the injuries ...
Voom has developed a multi-platform wellness pr...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
The Juhi Ash Center, located on Fifth Avenue and 61st Street, combines the best of...
The Juhi Ash Center, located on Fifth Avenue an...
Sunesis is a biopharmaceutical company focused on the development and commercializ...
Sunesis is a biopharmaceutical company focused ...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.